| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 758 |
| 1 | PEMBROLIZUMAB | 728 |
| 2 | IPILIMUMAB | 540 |
| 3 | CARBOPLATIN | 363 |
| 4 | PACLITAXEL | 260 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 218 |
| 6 | ATEZOLIZUMAB | 199 |
| 7 | BEVACIZUMAB | 164 |
| 8 | DURVALUMAB | 131 |
| 9 | PEMETREXED DISODIUM | 128 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TREMELIMUMAB | 69 | 0.0156 |
| 1 | ETRANACOGENE DEZAPARVOVEC | 1 | 0.0154 |
| 2 | AVOBENZONE, HOMOSALATE, OCTISALAT, OCTOCRYLENE | 2 | 0.0142 |
| 3 | AVOBENZONE, HOMOSALATE, OCTOCRYLENE, OCTISALATE | 2 | 0.0134 |
| 4 | PLATINUM | 7 | 0.0132 |
| 5 | IPILIMUMAB | 540 | 0.0123 |
| 6 | TITANIUM DIOXIDE | 2 | 0.0082 |
| 7 | NIVOLUMAB AND RELATLIMAB-RMBW | 4 | 0.0078 |
| 8 | NIVOLUMAB | 758 | 0.0077 |
| 9 | ALUMINUM HYDROXIDE GEL | 1 | 0.0068 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1665 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 608 |
| 2 | Platinum-based Drug [EPC] | 465 |
| 3 | Corticosteroid [EPC] | 280 |
| 4 | Microtubule Inhibitor [EPC] | 274 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 170 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 165 |
| 7 | Kinase Inhibitor [EPC] | 162 |
| 8 | Programmed Death Ligand-1 Blocker [EPC] | 149 |
| 9 | Folate Analog Metabolic Inhibitor [EPC] | 101 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1665 | 0.0169 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 608 | 0.0126 |
| 2 | Lymphocyte Activation Gene-3 Blocker [EPC] | 4 | 0.0078 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 149 | 0.0069 |
| 4 | Adrenal Steroid Synthesis Inhibitor [EPC] | 6 | 0.0060 |
| 5 | Platinum-based Drug [EPC] | 465 | 0.0017 |
| 6 | Microtubule Inhibitor [EPC] | 274 | 0.0017 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 13 | 0.0015 |
| 8 | CD38-directed Cytolytic Antibody [EPC] | 8 | 0.0014 |
| 9 | Prostacycline [EPC] | 1 | 0.0011 |